Contrave Advisory Committee Date May Give Orexigen Late-Mover Advantage
This article was originally published in The Pink Sheet Daily
Executive Summary
Earlier panel critiques of Contrave rivals should provide insight on how FDA is weighing risk versus benefit in obesity space.
You may also be interested in...
REMS Cannot Save Abbott's Obesity Drug Meridia In Face Of Cardiovascular Issues
Firm withdraws sibutramine as FDA finds no patient group for which risk mitigation would result in sufficient benefit.
REMS Cannot Save Abbott's Obesity Drug Meridia In Face Of Cardiovascular Issues
Firm withdraws sibutramine as FDA finds no patient group for which risk mitigation would result in sufficient benefit.
FDA's Woodcock On Obesity Drugs: It's Hard To Fight Mother Nature
FDA officials remain skeptical that a drug can be developed to treat morbid obesity and have acceptable side effects